Inovio Pharmaceuticals (INO) Set to Announce Earnings on Thursday

Inovio Pharmaceuticals (NASDAQ:INO) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, November 14th. Analysts expect Inovio Pharmaceuticals to post earnings of ($1.20) per share for the quarter.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.09). The company had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.10 million. During the same quarter in the prior year, the business posted ($1.56) earnings per share. On average, analysts expect Inovio Pharmaceuticals to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Inovio Pharmaceuticals Stock Performance

NASDAQ:INO opened at $5.65 on Thursday. The firm has a 50-day simple moving average of $5.99 and a 200-day simple moving average of $8.44. Inovio Pharmaceuticals has a one year low of $3.89 and a one year high of $14.75.

Wall Street Analyst Weigh In

INO has been the topic of several research analyst reports. Royal Bank of Canada dropped their target price on Inovio Pharmaceuticals from $8.00 to $7.00 and set a “sector perform” rating on the stock in a research note on Friday, October 4th. Oppenheimer decreased their price target on Inovio Pharmaceuticals from $40.00 to $33.00 and set an “outperform” rating for the company in a report on Monday, August 12th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $15.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, July 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Inovio Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $43.80.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.